Your browser is no longer supported. Please, upgrade your browser.
Settings
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-9.53 Insider Own0.30% Shs Outstand51.66M Perf Week-0.50%
Market Cap7.48B Forward P/E- EPS next Y-12.42 Insider Trans-19.61% Shs Float51.03M Perf Month-26.85%
Income-483.30M PEG- EPS next Q-3.02 Inst Own99.30% Short Float6.30% Perf Quarter-16.21%
Sales73.50M P/S101.70 EPS this Y-39.80% Inst Trans2.13% Short Ratio6.03 Perf Half Y-13.53%
Book/sh20.99 P/B6.52 EPS next Y-6.70% ROA-35.40% Target Price220.08 Perf Year-39.34%
Cash/sh21.12 P/C6.48 EPS next 5Y- ROE-40.00% 52W Range131.46 - 249.42 Perf YTD-37.73%
Dividend- P/FCF- EPS past 5Y-15.80% ROI-27.10% 52W High-45.06% Beta1.24
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low4.23% ATR7.81
Employees201 Current Ratio9.60 Sales Q/Q529.80% Oper. Margin- RSI (14)34.62 Volatility4.87% 5.15%
OptionableYes Debt/Eq0.00 EPS Q/Q20.80% Profit Margin- Rel Volume0.94 Prev Close136.76
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume532.99K Price137.03
Recom2.20 SMA20-9.78% SMA50-17.24% SMA200-17.43% Volume249,571 Change0.20%
Nov-19-21Initiated BMO Capital Markets Outperform $187
Sep-23-21Initiated Stifel Buy $202
Aug-26-21Initiated Morgan Stanley Equal-Weight $160
Jun-04-21Upgrade Citigroup Neutral → Buy
May-17-21Downgrade Oppenheimer Outperform → Perform
May-10-21Upgrade Jefferies Hold → Buy $208 → $196
Apr-26-21Resumed Credit Suisse Outperform $285
Dec-08-20Initiated JMP Securities Mkt Perform
Dec-08-20Initiated Evercore ISI Outperform
Nov-17-20Downgrade BofA Securities Neutral → Underperform $196
Nov-10-20Downgrade Jefferies Buy → Hold $206 → $208
Nov-10-20Downgrade Guggenheim Buy → Neutral $230
Nov-09-20Reiterated H.C. Wainwright Buy $233 → $265
Sep-28-20Initiated BofA Securities Neutral $172
Sep-18-20Downgrade Citigroup Buy → Neutral $127 → $183
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Mar-12-20Upgrade JP Morgan Underweight → Neutral $88
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-23-21 04:30PM  
08:53AM  
Nov-22-21 07:30AM  
Nov-18-21 10:13AM  
Nov-17-21 07:30AM  
Nov-15-21 11:20AM  
Nov-10-21 09:11PM  
Nov-09-21 04:23PM  
11:00AM  
09:00AM  
Nov-08-21 05:25PM  
04:01PM  
12:44PM  
Nov-05-21 05:15PM  
Nov-04-21 04:41AM  
Nov-02-21 08:47AM  
Nov-01-21 04:30PM  
02:33PM  
02:30PM  
02:05PM  
12:47PM  
Oct-27-21 03:03PM  
Oct-07-21 04:30PM  
Oct-04-21 04:30PM  
01:59PM  
Sep-24-21 04:15PM  
Sep-20-21 04:09PM  
12:09PM  
11:44AM  
09:45AM  
09:38AM  
09:19AM  
09:12AM  
08:20AM  
07:55AM  
07:55AM  
07:30AM  
Sep-19-21 09:47AM  
09:47AM  
Sep-15-21 04:15PM  
Aug-25-21 04:30PM  
Aug-10-21 01:47AM  
Aug-09-21 11:52AM  
Aug-05-21 04:15PM  
Jun-28-21 01:15PM  
Jun-25-21 09:27AM  
Jun-24-21 04:42PM  
Jun-17-21 10:45AM  
Jun-02-21 04:15PM  
06:13AM  
Jun-01-21 07:30AM  
07:30AM  
May-31-21 08:43AM  
May-29-21 05:33AM  
May-25-21 04:05PM  
May-04-21 11:17AM  
May-03-21 06:27AM  
Apr-29-21 06:51AM  
Apr-10-21 02:35PM  
Mar-31-21 07:30AM  
Mar-27-21 11:31AM  
Mar-23-21 10:52AM  
Mar-14-21 04:01AM  
Mar-12-21 11:54AM  
11:29AM  
Mar-10-21 04:39PM  
Feb-27-21 09:23AM  
Feb-18-21 04:15PM  
Feb-10-21 07:00AM  
Feb-08-21 05:47AM  
Feb-04-21 04:30PM  
Jan-26-21 12:00PM  
07:30AM  
Jan-20-21 08:00AM  
Jan-18-21 06:43AM  
Jan-12-21 08:00AM  
Jan-11-21 08:00AM  
Jan-07-21 04:43PM  
03:30PM  
08:26AM  
Jan-06-21 03:24PM  
01:52PM  
Jan-05-21 10:19AM  
Jan-04-21 05:56PM  
05:19PM  
Dec-28-20 06:37AM  
Dec-24-20 10:50AM  
08:26AM  
Dec-23-20 07:51PM  
12:01PM  
Dec-22-20 04:40PM  
10:15AM  
Dec-19-20 02:44PM  
Dec-15-20 08:53AM  
Dec-08-20 01:42PM  
12:32PM  
Dec-07-20 06:01AM  
04:43AM  
Dec-04-20 04:27PM  
11:31AM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM CHARLES MPresident & CEOJun 18Option Exercise8.4940,000339,600152,714Jun 21 05:12 PM
BAUM CHARLES MPresident & CEOJun 18Sale165.4640,0006,618,233112,714Jun 21 05:12 PM
Christensen JamieEVP, Chief Scientific OfficerMay 24Sale154.3443567,13853,850May 25 06:04 PM
CARTER BRUCE L ADirectorApr 05Option Exercise6.782,25015,2555,725Apr 06 08:06 PM
CARTER BRUCE L ADirectorApr 05Sale177.112,250398,5073,475Apr 06 08:06 PM
Hickey BenjaminEVP, Chief Commercial OfficerMar 19Option Exercise114.332,369270,84829,181Mar 22 04:42 PM
Hickey BenjaminEVP, Chief Commercial OfficerMar 19Sale176.442,369417,97826,812Mar 22 04:42 PM
Braslyn Ltd.10% OwnerMar 10Option Exercise0.0041003,135,967Mar 10 09:30 PM
Braslyn Ltd.10% OwnerMar 10Sale196.7641080,6723,135,557Mar 10 09:30 PM
Braslyn Ltd.10% OwnerMar 09Option Exercise0.0011,971123,135,967Mar 10 09:30 PM
Braslyn Ltd.10% OwnerMar 09Sale197.6711,9712,366,2523,123,996Mar 10 09:30 PM
Boxer Capital, LLC10% OwnerMar 05Option Exercise0.00611,4406112,363,004Mar 09 09:48 PM
Boxer Capital, LLC10% OwnerMar 05Sale181.15400,00572,460,905230,333Mar 09 09:48 PM
Cherrington Julie MDirectorMar 02Sale201.012,000402,0201,475Mar 04 05:25 PM
Faga DanielEVP, Chief Operating OfficerFeb 02Option Exercise114.331,340153,20231,978Feb 03 05:09 PM
CARTER BRUCE L ADirectorFeb 02Option Exercise6.782,25015,2555,725Feb 03 05:08 PM
CARTER BRUCE L ADirectorFeb 02Sale191.122,250430,0183,475Feb 03 05:08 PM
Faga DanielEVP, Chief Operating OfficerFeb 02Sale194.381,340260,46930,638Feb 03 05:09 PM
Martinez Maria EDirectorJan 29Option Exercise39.767,500298,20010,975Feb 01 09:47 PM
Martinez Maria EDirectorJan 29Sale203.547,5001,526,5843,475Feb 01 09:47 PM
BAUM CHARLES MPresident & CEOJan 26Option Exercise5.402,29212,377112,714Jan 28 05:45 PM
Johnson Craig ADirectorJan 21Option Exercise20.5415,000308,10018,475Jan 25 04:31 PM
Johnson Craig ADirectorJan 21Sale211.5515,0003,173,2033,475Jan 25 04:31 PM
BAUM CHARLES MPresident & CEOJan 19Option Exercise27.003,24587,615110,422Jan 20 06:17 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 07Sale216.3324152,1357,471Jan 08 07:57 PM
Hickey BenjaminEVP, Chief Commercial OfficerJan 07Sale216.332,078449,52519,789Jan 08 07:46 PM
Faga DanielEVP, Chief Operating OfficerJan 07Sale216.332,625567,85423,615Jan 08 07:15 PM
REED VICKIE SSVP, Chief Accounting OfficerJan 06Sale210.39538113,1907,712Jan 08 07:57 PM
Christensen JamieEVP, Chief Scientific OfficerJan 06Sale210.391,459306,96147,262Jan 08 07:15 PM
BAUM CHARLES MPresident & CEOJan 06Sale210.394,511949,06687,512Jan 08 07:14 PM
BAUM CHARLES MPresident & CEODec 18Option Exercise8.4940,000339,600142,023Dec 21 06:28 PM
BAUM CHARLES MPresident & CEODec 18Sale234.4840,0009,379,114102,023Dec 21 06:28 PM
FUCHS HENRY JDirectorDec 15Option Exercise20.5410,000205,40012,000Dec 16 05:37 PM
FUCHS HENRY JDirectorDec 15Sale233.3910,0002,333,9072,000Dec 16 05:37 PM
CARTER BRUCE L ADirectorDec 14Option Exercise6.782,25015,2554,250Dec 16 05:37 PM
GREY MICHAEL GDirectorDec 14Option Exercise16.8410,900183,55615,156Dec 16 05:36 PM
GREY MICHAEL GDirectorDec 14Sale245.4410,9002,675,3454,256Dec 16 05:36 PM
CARTER BRUCE L ADirectorDec 14Sale246.282,250554,1272,000Dec 16 05:37 PM